ES3001985T3 - Improved methods of assessing uch-l1 in patient samples - Google Patents

Improved methods of assessing uch-l1 in patient samples Download PDF

Info

Publication number
ES3001985T3
ES3001985T3 ES17791223T ES17791223T ES3001985T3 ES 3001985 T3 ES3001985 T3 ES 3001985T3 ES 17791223 T ES17791223 T ES 17791223T ES 17791223 T ES17791223 T ES 17791223T ES 3001985 T3 ES3001985 T3 ES 3001985T3
Authority
ES
Spain
Prior art keywords
uch
antibody
gfap
antibodies
hours
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES17791223T
Other languages
English (en)
Spanish (es)
Inventor
Saul Datwyler
Beth Mcquiston
Gangamani Beligere
Elaine Brate
John Ramp
David Pacenti
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Laboratories
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60186371&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES3001985(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Application granted granted Critical
Publication of ES3001985T3 publication Critical patent/ES3001985T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G01N33/535—Production of labelled immunochemicals with enzyme label or co-enzymes, co-factors, enzyme inhibitors or enzyme substrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/581—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with enzyme label (including co-enzymes, co-factors, enzyme inhibitors or substrates)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/02—Thioester hydrolases (3.1.2)
    • C12Y301/02015—Ubiquitin thiolesterase (3.1.2.15)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/978—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2871—Cerebrovascular disorders, e.g. stroke, cerebral infarct, cerebral haemorrhage, transient ischemic event
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • General Engineering & Computer Science (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
ES17791223T 2016-10-03 2017-10-02 Improved methods of assessing uch-l1 in patient samples Active ES3001985T3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662403293P 2016-10-03 2016-10-03
US201762455269P 2017-02-06 2017-02-06
PCT/US2017/054775 WO2018067468A1 (en) 2016-10-03 2017-10-02 Improved methods of assessing uch-l1 status in patient samples

Publications (1)

Publication Number Publication Date
ES3001985T3 true ES3001985T3 (en) 2025-03-06

Family

ID=60186371

Family Applications (2)

Application Number Title Priority Date Filing Date
ES17791223T Active ES3001985T3 (en) 2016-10-03 2017-10-02 Improved methods of assessing uch-l1 in patient samples
ES17791224T Active ES3060885T3 (en) 2016-10-03 2017-10-02 Improved methods of assessing gfap status in patient samples

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES17791224T Active ES3060885T3 (en) 2016-10-03 2017-10-02 Improved methods of assessing gfap status in patient samples

Country Status (10)

Country Link
US (4) US20180106800A1 (enExample)
EP (4) EP4521116A3 (enExample)
JP (2) JP2019530875A (enExample)
CN (2) CN110383068A (enExample)
AU (4) AU2017339809B2 (enExample)
BR (1) BR112019006710A2 (enExample)
CA (2) CA3036714A1 (enExample)
ES (2) ES3001985T3 (enExample)
MX (2) MX2019003473A (enExample)
WO (2) WO2018067474A1 (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7346300B2 (ja) 2017-03-23 2023-09-19 アボット・ラボラトリーズ 早期バイオマーカーであるユビキチンカルボキシ末端ヒドロラーゼｌ１を使用する、ヒト対象における外傷性脳損傷の程度の診断及び決定の一助となるための方法
EP3610268B1 (en) * 2017-04-15 2025-09-24 Abbott Laboratories Methods for aiding in the hyperacute diagnosis and determination of traumatic brain injury in a human subject using early biomarkers
JP7080899B2 (ja) 2017-04-28 2022-06-06 アボット・ラボラトリーズ 同じヒト対象に由来する少なくとも２つの試料に対して早期バイオマーカーを使用する、外傷性脳損傷の超急性の診断及び決定の一助となるための方法
US10866251B2 (en) 2017-05-25 2020-12-15 Abbott Laboratories Methods for aiding in the determination of whether to perform imaging on a human subject who has sustained or may have sustained an injury to the head using early biomarkers
WO2018222783A1 (en) 2017-05-30 2018-12-06 Abbott Laboratories Methods for aiding in diagnosing and evaluating a mild traumatic brain injury in a human subject using cardiac troponin i and early biomarkers
EP3649474A1 (en) 2017-07-03 2020-05-13 Abbott Laboratories Improved methods for measuring ubiquitin carboxy-terminal hydrolase l1 levels in blood
WO2019112863A1 (en) * 2017-12-06 2019-06-13 FloTBI Inc. Assay and point of care device utilizing saliva for diagnosis and treatment of neurological conditions affected brain health
WO2019113525A2 (en) 2017-12-09 2019-06-13 Abbott Laboratories Methods for aiding in the diagnosis and evaluation of a subject who has sustained an orthopedic injury and that has or may have sustained an injury to the head, such as mild traumatic brain injury (tbi), using glial fibrillary acidic protein (gfap) and/or ubiquitin carboxy-terminal hydrolase l1 (uch-l1)
WO2019112860A1 (en) 2017-12-09 2019-06-13 Abbott Laboratories Methods for aiding in diagnosing and evaluating a traumatic brain injury in a human subject using a combination of gfap and uch-l1
WO2019133717A1 (en) 2017-12-29 2019-07-04 Abbott Laboratories Novel biomarkers and methods for diagnosing and evaluating traumatic brain injury
EP3861342A4 (en) * 2018-10-05 2022-07-13 Children's Healthcare of Atlanta, Inc. BLOOD BIOMARKERS FOR SEVERE TRAUMATIC BRAIN INJURY
US20230135030A1 (en) 2018-11-26 2023-05-04 Baseline Global, Inc. Methods, Systems, and a Kit for Diagnosis, Detection, Monitoring & Treatment of Traumatic Brain Injury
US11389799B2 (en) 2019-01-17 2022-07-19 The Regents Of The University Of Michigan Microfluidic device for size and deformability measurements and applications thereof
TWI746142B (zh) * 2020-09-01 2021-11-11 費思科光電有限公司 檢測裝置、檢測系統及檢測方法
EP4211468A4 (en) * 2020-09-11 2024-10-09 Glympse Bio, Inc. DETECTION OF EX VIVO PROTEASE ACTIVITY FOR DETECTION/DIAGNOSTIC, STAGING, MONITORING AND TREATMENT OF DISEASES
CN112175079A (zh) * 2020-10-10 2021-01-05 武汉华美生物工程有限公司 一种多功能抗gfap单克隆抗体的制备方法及其应用
WO2022115705A2 (en) 2020-11-30 2022-06-02 Enigma Biointelligence, Inc. Non-invasive assessment of alzheimer's disease
WO2022266034A1 (en) 2021-06-14 2022-12-22 Abbott Laboratories Methods of diagnosing or aiding in diagnosis of brain injury caused by acoustic energy, electromagnetic energy, an over pressurization wave, and/or blast wind
CA3230038A1 (en) 2021-08-31 2023-03-09 Hongwei Zhang Methods and systems of diagnosing brain injury
CN118715440A (zh) 2021-08-31 2024-09-27 雅培实验室 诊断脑损伤的方法和系统
WO2023056268A1 (en) 2021-09-30 2023-04-06 Abbott Laboratories Methods and systems of diagnosing brain injury
JP2025507303A (ja) 2022-02-04 2025-03-18 アボット・ラボラトリーズ 試料におけるユビキチンカルボキシ末端ヒドロラーゼｌ１及び／又はグリア原線維性酸性タンパク質の存在を検出する又はその量を測定するためのラテラルフロー方法、アッセイ及びデバイス
WO2024006876A1 (en) 2022-06-29 2024-01-04 Abbott Laboratories Magnetic point-of-care systems and assays for determining gfap in biological samples
AU2023342055A1 (en) 2022-09-15 2025-03-13 Abbott Laboratories Biomarkers and methods for differentiating between mild and supermild traumatic brain injury
JP2026517628A (ja) 2023-04-04 2026-06-02 アボット・ラボラトリーズ 対象が亜急性後天性脳損傷（ａｂｉ）を負った、負った可能性がある、又は負っていると推測されるかどうかを決定するためのバイオマーカーの使用
WO2024226971A1 (en) 2023-04-28 2024-10-31 Abbott Point Of Care Inc. Improved assays, cartridges, and kits for detection of biomarkers, including brain injury biomarkers
WO2025043222A1 (en) * 2023-08-23 2025-02-27 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for diagnosing and treating age-related neuronal cell damage
WO2025182761A1 (ja) * 2024-03-01 2025-09-04 富士レビオ株式会社 Ｇｆａｐの検出方法、アルツハイマー病の診断を補助する方法、及びそれらに用いるキット
WO2025254995A1 (en) * 2024-06-04 2025-12-11 Women & Infants Hospital Of Rhode Island Methods comprising ubiquitin c-terminal hydrolase l1 (uchl1) for determining ovarian reserve
WO2026112563A1 (en) 2024-11-25 2026-05-28 Abbott Laboratories Systems and methods for tbi adjudication
CN119470922B (zh) * 2024-11-29 2026-04-21 长沙纽康度生物科技有限公司 一种用于创伤性脑损伤检测的生物标记物及其应用

Family Cites Families (119)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6492107B1 (en) 1986-11-20 2002-12-10 Stuart Kauffman Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique
DE3587814T2 (de) 1985-03-30 1994-11-10 Marc Ballivet Verfahren zum erhalten von dns, rns, peptiden, polypeptiden oder proteinen durch dns-rekombinant-verfahren.
US5618920A (en) 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5635600A (en) 1986-07-07 1997-06-03 Trustees Of Dartmouth College Bifunctional and heteroantibodies specific for the high affinity Fc receptor for immunoglobulin G on human mononuclear phagocytes
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4704692A (en) 1986-09-02 1987-11-03 Ladner Robert C Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
DE3750503T2 (de) 1986-10-22 1995-02-09 Abbott Lab Chemilumineszierende Acridinium- und Phenantridiniumsalze.
EP0279582A3 (en) 1987-02-17 1989-10-18 Pharming B.V. Dna sequences to target proteins to the mammary gland for efficient secretion
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
US5006309A (en) 1988-04-22 1991-04-09 Abbott Laboratories Immunoassay device with liquid transfer between wells by washing
US5089424A (en) 1988-06-14 1992-02-18 Abbott Laboratories Method and apparatus for heterogeneous chemiluminescence assay
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
DE68927933T2 (de) 1988-09-02 1997-08-14 Dyax Corp Herstellung und auswahl von rekombinantproteinen mit verschiedenen bindestellen
US5241070A (en) 1988-09-26 1993-08-31 Ciba Corning Diagnostics Corp. Nucleophilic polysubstituted aryl acridinium esters and uses thereof
US5063081A (en) 1988-11-14 1991-11-05 I-Stat Corporation Method of manufacturing a plurality of uniform microfabricated sensing devices having an immobilized ligand receptor
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5028535A (en) 1989-01-10 1991-07-02 Biosite Diagnostics, Inc. Threshold ligand-receptor assay
US5939272A (en) 1989-01-10 1999-08-17 Biosite Diagnostics Incorporated Non-competitive threshold ligand-receptor assays
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5780225A (en) 1990-01-12 1998-07-14 Stratagene Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
AU7247191A (en) 1990-01-11 1991-08-05 Molecular Affinities Corporation Production of antibodies using gene libraries
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US5922615A (en) 1990-03-12 1999-07-13 Biosite Diagnostics Incorporated Assay devices comprising a porous capture membrane in fluid-withdrawing contact with a nonabsorbent capillary network
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ES2139598T3 (es) 1990-07-10 2000-02-16 Medical Res Council Procedimientos para la produccion de miembros de parejas de union especifica.
CA2090126C (en) 1990-08-02 2002-10-22 John W. Schrader Methods for the production of proteins with a desired function
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
CA2072758A1 (en) 1990-09-14 1992-03-15 Kenneth Francis Buechler Antibodies to complexes of ligand receptors and ligands and their utility in ligand-receptor assays
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
DE69129154T2 (de) 1990-12-03 1998-08-20 Genentech, Inc., South San Francisco, Calif. Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
DE69233697T2 (de) 1991-03-01 2008-01-24 Dyax Corp., Cambridge Verfahren zur Entwicklung von bindenden Mikroproteinen
PT100379B (pt) 1991-04-10 1999-01-29 Scripps Research Inst Bibliotecas de receptores heterodimericos usando fagomideos
AU1772992A (en) 1991-04-10 1992-11-17 Biosite Diagnostics Incorporated Crosstalk inhibitors and their uses
EP0579767B1 (en) 1991-04-11 2000-08-23 Biosite Diagnostics Inc. Novel conjugates and assays for simultaneous detection of multiple ligands
CA2069530A1 (en) 1991-06-03 1992-12-04 Cass J. Grandone Reagent pack for immunoassays
JPH07503124A (ja) 1991-06-14 1995-04-06 ゾーマ・コーポレーション 微生物によって生産される抗体断片とそれらの複合体
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
DE69233528T2 (de) 1991-11-25 2006-03-16 Enzon, Inc. Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
WO1993011794A1 (en) 1991-12-13 1993-06-24 Xoma Corporation Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5352803A (en) 1992-03-30 1994-10-04 Abbott Laboratories 5(6)-methyl substituted fluorescein derivatives
EP0649533B1 (en) 1992-03-30 2000-05-10 Abbott Laboratories Reagents and methods for the detection and quantification of thyroxine in fluid samples
US6019944A (en) 1992-05-21 2000-02-01 Biosite Diagnostics, Inc. Diagnostic devices and apparatus for the controlled movement of reagents without membranes
US6143576A (en) 1992-05-21 2000-11-07 Biosite Diagnostics, Inc. Non-porous diagnostic devices for the controlled movement of reagents
ES2301158T3 (es) 1992-07-24 2008-06-16 Amgen Fremont Inc. Produccion de anticuerpos xenogenicos.
US5824799A (en) 1993-09-24 1998-10-20 Biosite Diagnostics Incorporated Hybrid phthalocyanine derivatives and their uses
JPH09506262A (ja) 1993-12-08 1997-06-24 ジェンザイム・コーポレイション 特異的抗体の製造方法
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
ES2201097T3 (es) 1994-01-31 2004-03-16 Trustees Of Boston University Bibliotecas de anticuerpos policlonales.
JPH09510201A (ja) 1994-03-07 1997-10-14 メダレツクス・インコーポレーテツド 臨床的効用を有する二重特異性分子
US5516637A (en) 1994-06-10 1996-05-14 Dade International Inc. Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
US6111166A (en) 1994-09-19 2000-08-29 Medarex, Incorporated Transgenic mice expressing human Fcα and β receptors
US6130364A (en) 1995-03-29 2000-10-10 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
US6091001A (en) 1995-03-29 2000-07-18 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
AU705616B2 (en) 1995-04-21 1999-05-27 Cell Genesys, Inc. Generation of large genomic DNA deletions
CA2219361C (en) 1995-04-27 2012-02-28 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6410690B1 (en) 1995-06-07 2002-06-25 Medarex, Inc. Therapeutic compounds comprised of anti-Fc receptor antibodies
JP2978435B2 (ja) 1996-01-24 1999-11-15 チッソ株式会社 アクリロキシプロピルシランの製造方法
ATE239041T1 (de) 1996-02-09 2003-05-15 Basf Ag Humane antikörper welche an humanen tnfalpha binden
US5714352A (en) 1996-03-20 1998-02-03 Xenotech Incorporated Directed switch-mediated DNA recombination
US6699658B1 (en) 1996-05-31 2004-03-02 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
US5922845A (en) 1996-07-11 1999-07-13 Medarex, Inc. Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
US6113855A (en) 1996-11-15 2000-09-05 Biosite Diagnostics, Inc. Devices comprising multiple capillarity inducing surfaces
EP1972194A1 (en) 1996-12-03 2008-09-24 Amgen Fremont Inc. Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom
US6017517A (en) 1996-12-18 2000-01-25 The Dial Corporation Method for treating human nails
IL131016A (en) 1997-01-21 2004-12-15 Gen Hospital Corp Selection of proteins using RNA-protein blends
US5947124A (en) 1997-03-11 1999-09-07 Biosite Diagnostics Incorporated Diagnostic for determining the time of a heart attack
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
WO1999028349A2 (en) 1997-12-02 1999-06-10 Medarex, Inc. CELLS EXPRESSING ANTI-Fc RECEPTOR BINDING COMPONENTS
KR20010034554A (ko) 1998-03-03 2001-04-25 레이몬드, 엠. 위티 치료제로서의 ｃｄ147 결합 분자
US20020029391A1 (en) 1998-04-15 2002-03-07 Claude Geoffrey Davis Epitope-driven human antibody production and gene expression profiling
JP2002522063A (ja) 1998-08-17 2002-07-23 アブジェニックス インコーポレイテッド 増加した血清半減期を有する改変された分子の生成
AU1728800A (en) 1998-11-18 2000-06-05 Genentech Inc. Antibody variants with higher binding affinity compared to parent antibodies
ES2706547T3 (es) 1998-12-23 2019-03-29 Pfizer Anticuerpos monoclonales humanos para CTLA-4
US6231768B1 (en) 1999-01-19 2001-05-15 Nalco Chemical Company Rheology modification of settled solids in mineral processing
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
BR0009323A (pt) 1999-03-25 2002-01-08 Knoll Gmbh Anticorpos humanos que ligam a il-12 humana e métodos para a produção
NZ517202A (en) 1999-08-24 2004-05-28 Medarex Inc Human CTLA-4 antibodies and their uses
SK12942002A3 (sk) 2000-02-10 2003-05-02 Abbott Laboratories Protilátky viažuce ľudský interleukín-18, spôsoby ich výroby a použitia
PE20020132A1 (es) 2000-06-29 2002-03-04 Abbott Lab Anticuerpos de especificidad doble y metodos para la elaboracion y el uso de los mismos
US20030186374A1 (en) 2001-10-01 2003-10-02 Hufton Simon E. Multi-chain eukaryotic display vectors and uses thereof
US7419821B2 (en) 2002-03-05 2008-09-02 I-Stat Corporation Apparatus and methods for analyte measurement and immunoassay
US20060134713A1 (en) 2002-03-21 2006-06-22 Lifescan, Inc. Biosensor apparatus and methods of use
US20040018577A1 (en) 2002-07-29 2004-01-29 Emerson Campbell John Lewis Multiple hybrid immunoassay
US7682833B2 (en) 2003-09-10 2010-03-23 Abbott Point Of Care Inc. Immunoassay device with improved sample closure
US7723099B2 (en) 2003-09-10 2010-05-25 Abbott Point Of Care Inc. Immunoassay device with immuno-reference electrode
EP1519194A1 (en) * 2003-09-24 2005-03-30 Roche Diagnostics GmbH Use of gfap for identification of intracerebral hemorrhage
EP1745149A4 (en) * 2004-04-15 2008-08-06 Univ Florida NEURALE PROTEINS AS BIOMARKERS FOR INJURY TO THE NERVOUS SYSTEM AND OTHER NEURAL DISORDERS
US20140303041A1 (en) * 2004-04-15 2014-10-09 University Of Florida Research Foundation Inc. In vitro diagnostic devices for nervous system injury and other neural disorders
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
KR20140053410A (ko) 2005-08-19 2014-05-07 아보트 러보러터리즈 이원 가변 도메인 면역글로불린 및 이의 용도
CA2715248A1 (en) * 2008-02-04 2009-08-13 Banyan Biomarkers, Inc. Process to diagnose or treat brain injury
EP3336551B1 (en) * 2008-08-11 2023-05-31 Banyan Biomarkers, Inc. Biomarker detection process and assay of neurological condition
JP5875514B2 (ja) * 2009-06-19 2016-03-02 バンヤン・バイオマーカーズ・インコーポレーテッド 神経学的状態のバイオマーカーアッセイ
WO2011011334A2 (en) * 2009-07-18 2011-01-27 Banyan Biomarkers, Inc. SYNERGISTIC BIOMARKER ASSAY OF NEUROLGICAL CONDITION USING S-100β
US20130029362A1 (en) * 2010-04-01 2013-01-31 Andreas Jeromin Markers and assays for detection of neurotoxicity
WO2012051519A2 (en) * 2010-10-14 2012-04-19 The Johns Hopkins University Biomarkers of brain injury
US20120322682A1 (en) * 2011-06-20 2012-12-20 William Marsh Rice University Brain injury biomarker panel
CN105378099B (zh) * 2013-03-14 2021-05-11 雅培制药有限公司 Hcv核心脂质结合结构域单克隆抗体
US9157910B2 (en) * 2013-03-15 2015-10-13 Abbott Laboratories Assay with increased dynamic range
US20150141528A1 (en) * 2013-05-31 2015-05-21 Banyan Biomarkers, Inc. Neural specific s100b for biomarker assays and devices for detection of a neurological condition
EP3022322A4 (en) * 2013-07-17 2017-05-17 The Johns Hopkins University A multi-protein biomarker assay for brain injury detection and outcome
WO2015066211A1 (en) * 2013-10-29 2015-05-07 Banyan Biomarkers, Inc. Uch-l1 isoforms, assays and devices for detection of a neurological condition
US20150224499A1 (en) * 2014-02-13 2015-08-13 SFC Fluidics, Inc. Automated Microfluidic Sample Analyzer Platforms for Point of Care
CA2943396A1 (en) * 2014-04-07 2015-10-15 Iron Horse Diagnostics, Inc. Traumatic brain injury and neurodegenerative biomarkers, methods, and systems
AU2015323168B2 (en) * 2014-09-22 2020-07-02 Japan Science And Technology Agency Method for detecting target molecule, and kit for use in said method
EP3702786A1 (en) * 2014-10-06 2020-09-02 Université de Genève Markers and their use in brain injury
CA2981515A1 (en) 2015-04-03 2016-10-06 Abbott Laboratories Devices and methods for sample analysis
JP2018518655A (ja) 2015-04-03 2018-07-12 アボット・ラボラトリーズＡｂｂｏｔｔ Ｌａｂｏｒａｔｏｒｉｅｓ サンプル分析用デバイス及び方法
CN105085629A (zh) * 2015-08-12 2015-11-25 浙江聚康生物工程有限公司 人gfap抗原决定簇多肽、抗体及其体外诊断试剂盒

Also Published As

Publication number Publication date
US20220003786A1 (en) 2022-01-06
BR112019006710A2 (pt) 2019-06-25
MX2019003473A (es) 2019-10-15
NZ751532A (en) 2026-01-30
ES3060885T3 (en) 2026-03-30
MX420781B (es) 2025-02-10
EP3519824A1 (en) 2019-08-07
CA3036714A1 (en) 2018-04-12
JP2019530875A (ja) 2019-10-24
US20220050111A1 (en) 2022-02-17
EP3519824B1 (en) 2024-11-20
EP3519825B1 (en) 2025-11-19
BR112019006706A2 (pt) 2019-06-25
EP4729943A3 (en) 2026-07-01
AU2022203320B2 (en) 2025-02-13
EP4521116A2 (en) 2025-03-12
WO2018067468A1 (en) 2018-04-12
AU2022203322A1 (en) 2022-06-09
JP2019535015A (ja) 2019-12-05
CN110249226B (zh) 2023-08-25
US20180106818A1 (en) 2018-04-19
EP4521116A3 (en) 2025-05-28
AU2017339858B2 (en) 2022-02-17
AU2022203320A1 (en) 2022-06-09
CA3036717A1 (en) 2018-04-12
AU2017339809A1 (en) 2019-04-04
EP4729943A2 (en) 2026-04-22
EP3519825A1 (en) 2019-08-07
NZ751522A (en) 2026-01-30
CN110249226A (zh) 2019-09-17
AU2017339858A1 (en) 2019-04-04
AU2017339809B2 (en) 2022-02-17
WO2018067474A1 (en) 2018-04-12
US20180106800A1 (en) 2018-04-19
MX2019003474A (es) 2019-10-07
CN110383068A (zh) 2019-10-25
AU2022203322B2 (en) 2024-06-27

Similar Documents

Publication Publication Date Title
AU2022203322B2 (en) Improved methods of assessing UCH-L1 status in patient samples
US20260072042A1 (en) Methods for aiding in diagnosing and evaluating a traumatic brain injury in a human subject using a combination of gfap and uch-l1
US12092647B2 (en) Methods for aiding in the determination of whether to perform imaging on a human subject who has sustained or may have sustained an injury to the head using early biomarkers
ES3055047T3 (en) Methods for aiding in the hyperacute diagnosis and determination of traumatic brain injury in a human subject using early biomarkers
ES3053676T3 (en) Methods for aiding in the hyperacute diagnosis and determination of traumatic brain injury using early biomarkers on at least two samples from the same human subject
US20250003988A1 (en) Use of one or more biomarkers to determine traumatic brain injury (tbi) in a human subject having received a head computerized tomography scan that is negative for a tbi
US20240094226A1 (en) Biomarkers for use in determining traumatic brain injury (tbi)
US20230213536A1 (en) Use of biomarkers to determine sub-acute traumatic brain injury (tbi) in a subject having received a head computerized tomography (ct) scan that is negative for a tbi or no head ct scan
US20220381796A1 (en) Methods of evaluating brain injury in a pediatric subject
HK40123156A (en) Improved methods of assessing uch-l1 status in patient samples
BR112019006706B1 (pt) Métodos para avaliar o estado da proteína glial fibrilar ácida e para medir produto de decomposição de proteína glial fibrilar ácida em amostras biológicas de indivíduos
BR122024019574A2 (pt) Métodos para avaliar um indivíduo humano quanto a uma lesão na cabeça